Last updated: September 1, 2026

KONAKION is a mature vitamin K1, or phytomenadione, brand used to prevent and treat vitamin K deficiency bleeding and to reverse excessive anticoagulation. Its commercial position is driven by hospital procurement, neonatal protocols, emergency medicine, and supply reliability rather than clinical differentiation. The product has no meaningful period of market exclusivity, and its patent barriers are not material to generic competition.

Standalone KONAKION revenue is not publicly reported by Roche. The brand’s financial trajectory is therefore best assessed through product maturity, geographic availability, generic substitution, hospital tender pricing, and the economics of injectable vitamin K products.

What is KONAKION and who owns the product?

KONAKION contains phytomenadione, the synthetic form of vitamin K1. The product is marketed in several countries as KONAKION MM, using a mixed-micellar formulation designed to improve aqueous dispersion and parenteral administration.

Attribute	KONAKION profile
Active ingredient	Phytomenadione, also called phytonadione or vitamin K1
Therapeutic class	Vitamin replacement; hemostatic support
Primary uses	Vitamin K deficiency, vitamin K deficiency bleeding, excessive anticoagulation
Common dosage forms	Oral and injectable formulations, depending on jurisdiction
Key clinical settings	Neonatal care, emergency medicine, surgery, anticoagulation reversal
Original multinational company	Roche
Current U.K. marketing authorization holder	Roche Products Limited for listed KONAKION products
U.S. equivalent brand	Mephyton, not KONAKION
Market status	Mature, multisource, low-growth pharmaceutical market

Roche’s country-specific subsidiaries hold or commercialize KONAKION registrations in selected markets. Ownership and marketing arrangements vary by jurisdiction, and the product is not marketed under the same brand name globally. Roche’s financial reporting does not identify KONAKION as a separate revenue line [1].

How does KONAKION work and what clinical demand supports the market?

Phytomenadione supports hepatic production of vitamin K-dependent clotting factors. Its principal demand sources are established clinical protocols rather than new prescribing growth.

KONAKION is used for:

Prevention of vitamin K deficiency bleeding in newborns.
Treatment of vitamin K deficiency caused by malabsorption, inadequate intake, or other clinical conditions.
Reversal of excessive anticoagulation associated with vitamin K antagonists such as warfarin.
Perioperative and emergency management where correction of coagulation abnormalities is required.

The neonatal market provides recurring institutional demand. Hospitals often purchase vitamin K products through formularies, group purchasing organizations, or public tenders. The anticoagulation-reversal market is clinically important but commercially constrained because demand depends on anticoagulant use, testing practices, and local treatment protocols.

Direct oral anticoagulants have reduced reliance on warfarin in many markets. That trend limits the growth of vitamin K products for anticoagulant reversal, although warfarin remains widely used in certain patient populations and health systems. KONAKION retains demand in neonatal care and vitamin K deficiency treatment, where newer anticoagulants have no direct relevance.

What is the FDA regulatory status of KONAKION?

KONAKION is not the principal U.S. brand. The U.S. market uses phytonadione products, including Mephyton tablets and injectable phytonadione products marketed by other manufacturers.

The FDA-approved U.S. product Mephyton contains phytonadione and is indicated for hypoprothrombinemia caused by vitamin K deficiency or interference with vitamin K activity [2]. U.S. injectable phytonadione products are subject to separate product approvals and labeling requirements.

Regulatory issue	KONAKION position
FDA-approved KONAKION brand	No major U.S. KONAKION brand presence identified
U.S. reference product	Phytonadione products, including Mephyton
European regulatory status	National and, depending on market, established products under local authorization
Prescription status	Generally prescription or hospital-controlled
Pediatric use	Important, especially neonatal prophylaxis
Regulatory exclusivity	Expired or not commercially relevant

KONAKION’s U.S. absence reduces the relevance of U.S. brand-specific exclusivity analysis. Generic competition in the United States is directed at phytonadione reference products rather than at a KONAKION-branded reference product.

What is the Orange Book status of KONAKION?

KONAKION is not a primary Orange Book-listed U.S. reference brand. The Orange Book analysis therefore applies to U.S. phytonadione reference products, including Mephyton where applicable, rather than to the European KONAKION brand [3].

No commercially significant, current Orange Book patent estate is associated with the historical vitamin K1 active ingredient. Phytomenadione is an established compound with decades of clinical use. Any historical composition, formulation, or manufacturing patents would generally have expired well before the current market period.

The commercial consequence is direct: a generic manufacturer does not face a meaningful active-ingredient patent barrier when developing a conventional phytonadione product. The main barriers are regulatory, manufacturing, quality, and supply-chain related.

What patents protect KONAKION?

No active core patent protection is expected to protect phytomenadione itself or the historical KONAKION brand.

Potential historical protection areas include:

Mixed-micellar solubilization systems.
Injectable stability and excipient combinations.
Container and light-protection systems.
Manufacturing processes for sterile vitamin K formulations.
Pediatric or neonatal administration formats.

These categories do not create a durable modern exclusivity position. Formulation patents can affect a specific product only while enforceable and only if the generic product practices the claimed technology. For KONAKION, the greater risk to competitors is likely regulatory equivalence and technical performance, not patent litigation.

The mixed-micellar formulation may create manufacturing complexity because injectable vitamin K products must meet sterility, stability, particulate, container-closure, and compatibility requirements. That complexity can delay entry or reduce the number of reliable suppliers, but it does not equal patent exclusivity.

When did KONAKION lose exclusivity?

KONAKION lost practical exclusivity decades ago because phytomenadione is an old active ingredient and the principal formulation technologies are mature. No current data indicates a remaining period of market exclusivity that could support premium pricing.

Exclusivity category	Current assessment
Active-ingredient patent	Expired
Core product patent	No commercially material active protection identified
Regulatory exclusivity	Expired or unavailable for this mature product
Orphan exclusivity	Not a principal market protection mechanism
Pediatric exclusivity	Not a current commercial barrier
Data exclusivity	Not a meaningful barrier for established formulations

The distinction between legal exclusivity and practical market concentration is important. A product can have no patent protection and still maintain share if hospitals prefer a known supplier, if competitors face manufacturing problems, or if procurement contracts favor continuity of supply.

How strong is the KONAKION patent estate?

The patent estate is weak from a life-cycle-management perspective. Its commercial durability comes from brand recognition, clinical familiarity, regulatory history, and supply dependability.

Patent-estate factor	Assessment
Active ingredient	Very weak
New chemical entity protection	None
Broad formulation protection	Unlikely to remain enforceable
Method-of-use protection	Limited commercial relevance
Device protection	Limited, jurisdiction-specific
Manufacturing know-how	More relevant than patents
Litigation leverage	Low
Generic launch deterrence	Low

A competitor could still face technical challenges when reproducing an injectable mixed-micellar formulation. These include precipitation, local tolerability, stability under light exposure, and consistency across production lots. Those issues can create regulatory delay, but they do not provide the originator with long-term exclusivity.

What generic entry risks exist for KONAKION?

Generic and multisource competition is structurally high. The product has an old active ingredient, established clinical use, and limited opportunity for meaningful differentiation.

The principal generic-entry pathways are:

Conventional phytonadione tablets or injectable products.
Nationally authorized equivalents to KONAKION MM.
Hospital-compounded or institutional alternatives where legally permitted.
Products using different excipient systems but the same active ingredient.
Tender-based substitution in public and hospital markets.

In Europe, substitution depends on national authorization, reference-product requirements, and procurement rules. In the United States, competitors generally target FDA-approved phytonadione products through abbreviated or other applicable pathways.

Paragraph IV litigation risk is low for the KONAKION brand because the U.S. brand is not the central reference product. Any Paragraph IV dispute would more likely concern patents listed against a U.S. phytonadione reference product. No widely reported, commercially material current Paragraph IV campaign specifically directed at KONAKION is evident from the product’s mature market position.

What formulation barriers protect KONAKION?

The mixed-micellar injectable formulation is the most important technical feature associated with KONAKION MM. Formulation performance can affect regulatory approval and physician confidence, especially for neonatal and intravenous use.

Relevant barriers include:

Sterile manufacturing capacity.
Consistent micellar dispersion.
Stability across the labeled shelf life.
Compatibility with administration systems.
Low particulate burden.
Control of injection-site reactions.
Protection from light and temperature excursions.
Demonstration of equivalent clinical performance.

These factors can support a modest brand premium in hospital procurement. They are more likely to produce short-term supply advantages than permanent market protection.

What litigation and settlement agreements affect KONAKION?

No major, currently material patent litigation or settlement agreement is widely associated with KONAKION. The product’s age and lack of meaningful patent exclusivity reduce the incentive for originator-generic settlement structures.

The principal legal risks are more likely to involve:

Product liability.
Manufacturing deviations.
Sterility failures.
Regulatory compliance.
Labeling and pharmacovigilance.
Supply-contract disputes.
Trademark use in national markets.

This differs from high-value oncology, immunology, or rare-disease products, where patent settlements can determine generic entry dates and billions of dollars in revenue exposure.

What is the financial trajectory for KONAKION?

Roche does not disclose standalone KONAKION revenue in its public annual reporting. The product is not reported as a separate growth driver, and its sales are embedded within broader pharmaceutical or regional reporting categories [1].

The likely financial profile is:

Financial dimension	Assessment
Revenue stage	Mature
Volume growth	Low; linked to population, hospital utilization, and protocols
Price growth	Constrained by generics and tenders
Margin profile	Sensitive to sterile manufacturing and distribution costs
Revenue concentration	Distributed across hospital and institutional markets
Brand premium	Possible but limited
Forecast risk	Supply disruption and competitor entry
Strategic value	Portfolio continuity rather than major growth

KONAKION’s revenue trajectory is likely flatter and less visible than Roche’s major oncology, immunology, and neuroscience products. The brand may retain defensible revenue in markets where physicians recognize the product and hospitals value consistent supply. It lacks the characteristics of a product capable of generating material long-term pharmaceutical growth.

Financial performance is likely to vary by country. In a branded retail market, KONAKION may maintain higher pricing through physician familiarity. In a centralized hospital market, tender competition can compress prices rapidly. Injectable formulations may preserve better economics than basic oral products because sterile manufacturing limits the supplier base.

How does KONAKION compare with generic phytonadione products?

Factor	KONAKION	Generic phytonadione
Brand recognition	High in markets where marketed	Low to moderate
Active ingredient	Phytomenadione	Phytomenadione
Formulation differentiation	Mixed-micellar versions in relevant markets	Varies by product
Patent protection	Not materially available	Same position
Regulatory burden	Established product history	Approval and equivalence burden
Hospital pricing	Potential brand premium	Usually lower
Supply advantage	Depends on Roche or local distributor	Depends on manufacturer
Generic substitution risk	High	Competitive market
Clinical differentiation	Limited	Limited

KONAKION’s strongest advantage is familiarity. Its weakest point is the absence of durable exclusivity.

What geographic markets are most important for KONAKION?

KONAKION is primarily a non-U.S. brand opportunity. Its commercial relevance depends on national product registrations and local supply arrangements.

Important market characteristics include:

Europe: established brand recognition and hospital use, with national differences in reimbursement and substitution.
United Kingdom: Roche-associated KONAKION products remain identifiable through national product information and prescribing systems [4].
Asia-Pacific: demand can be supported by neonatal care and hospital procurement, but local generic competition varies.
Emerging markets: price sensitivity and distributor access can outweigh brand strength.
United States: the relevant opportunity is phytonadione rather than KONAKION-branded commercialization.

What is the competitive outlook for KONAKION?

Competition will remain price-led and supply-led. The main risks are low-cost generic products, tender losses, local substitution, and disruption in sterile injectable supply.

The commercial upside is limited. Demand is stable because vitamin K remains clinically necessary, but the market has little room for premium innovation. A manufacturer could improve economics through:

Reliable neonatal supply.
Contract manufacturing.
Regional tender participation.
Improved packaging and administration convenience.
Portfolio bundling with coagulation or hospital products.
Regulatory approvals in markets with limited suppliers.

Biosimilar risk is not relevant. KONAKION is a small-molecule vitamin product, not a biologic. The competitive threat comes from generics and multisource phytonadione products.

Key Takeaways

KONAKION is a mature phytomenadione brand with stable clinical demand and limited growth potential.
Roche does not publicly disclose standalone KONAKION revenue.
The product has no meaningful current active-ingredient or core-product patent protection.
U.S. competition centers on phytonadione products such as Mephyton, not primarily on the KONAKION brand.
Paragraph IV risk specific to KONAKION is low, while generic substitution risk is high.
The mixed-micellar injectable formulation creates technical and manufacturing barriers but not durable exclusivity.
Financial performance depends on hospital tenders, neonatal protocols, pricing, and supply reliability.
Biosimilars are irrelevant; generic vitamin K1 products are the material competitive threat.
KONAKION’s strategic value is portfolio continuity and institutional demand, not high-growth revenue generation.

FAQs about KONAKION market dynamics

Is KONAKION still protected by patents?

No meaningful current patent protection is expected for the phytomenadione active ingredient or the historical core KONAKION product. Any remaining formulation or process rights would be jurisdiction-specific and unlikely to create broad market exclusivity.

Can generic manufacturers substitute for KONAKION MM?

In many markets, authorized phytonadione products can compete with or substitute for KONAKION, subject to national regulatory, prescribing, and procurement rules. Injectable formulation differences may affect interchangeability.

Does KONAKION have FDA approval in the United States?

KONAKION is not the principal U.S. brand. FDA-approved U.S. products contain phytonadione and include products such as Mephyton and injectable alternatives.

What is the main commercial risk to KONAKION?

The main risk is loss of hospital and tender share to lower-priced generic phytonadione products. Supply interruptions and changes in neonatal or anticoagulation protocols also affect demand.

Is KONAKION a biologic or biosimilar product?

No. KONAKION is a small-molecule vitamin K1 product. Its competitive landscape involves generic drugs, not biosimilars.

References

Roche Holding Ltd. (2024). Annual report 2023. Roche.
U.S. Food and Drug Administration. (n.d.). Mephyton (phytonadione) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
Electronic Medicines Compendium. (n.d.). Konakion MM 10 mg/1 ml solution for injection or infusion: Summary of product characteristics. Datapharm.
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	1
Patent Applications:	6,805
DailyMed Link:	KONAKION at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	KONAKION	phytonadione	INJECTABLE;INJECTION	011745-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Roche	KONAKION	phytonadione	INJECTABLE;INJECTION	011745-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

KONAKION Drug Patent Profile

Which patents cover Konakion, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Konakion

AI Deep Research

Questions you can ask:

Summary for KONAKION

Recent Clinical Trials for KONAKION

US Patents and Regulatory Information for KONAKION

KONAKION Market Dynamics, Financial Trajectory, Patent Position, and Generic Competition